ViiV Healthcare press release
ViiV Healthcare announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV. Results show a single-dose injection could maintain drug levels for up to six months. In-vitro data from a separate study demonstrate improved potency and an enhanced resistance profile versus bictegravir in resistant HIV strains.
Additional data from ViiV Healthcare’s long-acting pipeline presented at CROI 2026 show VH499, an investigational capsid inhibitor, was generally well tolerated and support the potential for ultra long-acting twice-yearly dosing.
Read the full press release here.
SEE ALSO:
Source : ViiV Healthcare
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.